^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

YE-NEO 001

i
Other names: YE-NEO 001, neoepitope yeast vaccine
Associations
Company:
ImmunityBio
Drug class:
Immunostimulant
Related drugs:
Associations
over1year
QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers. (clinicaltrials.gov)
P1, N=16, Active, not recruiting, NantBioScience, Inc. | Unknown status --> Active, not recruiting | Trial completion date: Dec 2020 --> Dec 2025 | Trial primary completion date: Dec 2019 --> Jul 2025
Enrollment closed • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HR positive + HER-2 positive
|
YE-NEO 001